We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Restructuring Efforts Aid Ameriprise (AMP), High Costs a Woe
Read MoreHide Full Article
Supported by a solid balance sheet, Ameriprise Financial, Inc. (AMP - Free Report) is well positioned for organic as well as inorganic growth. Moreover, its efficient capital deployment activities should continue enhancing shareholder value. However, consistently increasing expenses and elevated levels of outflows in the Asset Management segment remain causes for concern.
The company’s shares have gained 13.4% in the past year, underperforming 17.3% growth for the industry it belongs to.
Notably, its Zacks Consensus Estimate for current-year earnings has remained stable over the last 30 days. Thus, the stock currently carries a Zacks Rank #3 (Hold).
Looking at the fundamentals, the company’s revenues have witnessed a CAGR of 1.8% over the last five years (2013-2017). In order to face competition and keep pace with the changing market needs, Ameriprise has been modifying its products and services consistently. Moreover, its efforts to launch new products should further support top-line growth in the future.
The company’s inorganic growth story also remains impressive. From time to time, it has restructured its portfolio through acquisitions, sales and spin-offs. In fact, with an aim to remain profitable, it is likely to continue with the restructuring initiatives.
However, over the last five years (2013-2017), the company’s expenses have witnessed a CAGR of 1.5%. Elevated costs, mainly because of advertising campaign and technology upgrades, are expected to hurt bottom-line growth in the quarters ahead.
Further, elevated levels of outflows in the Asset Management segment, which is one of the major sources of the company’s revenues remains a cause for concern. Management expects outflows to continue in the coming quarters (albeit at a slower pace), which is likely to affect the segment’s performance.
Stocks to Consider
Some better-ranked stocks in the same space are Waddell & Reed Financial, Inc. , Lazard Ltd (LAZ - Free Report) and Virtus Investment Partners, Inc. (VRTS - Free Report) .
Waddell & Reed’s earnings estimates for the current year have been revised 12% upward over the last 60 days. Also, its shares gained 16.2% in a year’s time. The stock currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Lazard’s current-year earnings estimates have been revised 3.1% upward over the last 60 days. Its shares increased 12.4% in the last year. It has a Zacks Rank #2 (Buy).
Virtus Investment Partners also carries a Zacks Rank of 2. Its current-year earnings estimates have been revised 4.1% upward over the last 60 days. Its share price has increased 17.1% in the last year.
Investor Alert: Breakthroughs Pending
A medical advance is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating substantial revenue, and even more wondrous products are in the pipeline.
Cures for a variety of deadly diseases are in sight, and so are big potential profits for early investors. Zacks names 5 stocks to buy now.
Image: Bigstock
Restructuring Efforts Aid Ameriprise (AMP), High Costs a Woe
Supported by a solid balance sheet, Ameriprise Financial, Inc. (AMP - Free Report) is well positioned for organic as well as inorganic growth. Moreover, its efficient capital deployment activities should continue enhancing shareholder value. However, consistently increasing expenses and elevated levels of outflows in the Asset Management segment remain causes for concern.
.jpg)
The company’s shares have gained 13.4% in the past year, underperforming 17.3% growth for the industry it belongs to.
Notably, its Zacks Consensus Estimate for current-year earnings has remained stable over the last 30 days. Thus, the stock currently carries a Zacks Rank #3 (Hold).
Looking at the fundamentals, the company’s revenues have witnessed a CAGR of 1.8% over the last five years (2013-2017). In order to face competition and keep pace with the changing market needs, Ameriprise has been modifying its products and services consistently. Moreover, its efforts to launch new products should further support top-line growth in the future.
The company’s inorganic growth story also remains impressive. From time to time, it has restructured its portfolio through acquisitions, sales and spin-offs. In fact, with an aim to remain profitable, it is likely to continue with the restructuring initiatives.
However, over the last five years (2013-2017), the company’s expenses have witnessed a CAGR of 1.5%. Elevated costs, mainly because of advertising campaign and technology upgrades, are expected to hurt bottom-line growth in the quarters ahead.
Further, elevated levels of outflows in the Asset Management segment, which is one of the major sources of the company’s revenues remains a cause for concern. Management expects outflows to continue in the coming quarters (albeit at a slower pace), which is likely to affect the segment’s performance.
Stocks to Consider
Some better-ranked stocks in the same space are Waddell & Reed Financial, Inc. , Lazard Ltd (LAZ - Free Report) and Virtus Investment Partners, Inc. (VRTS - Free Report) .
Waddell & Reed’s earnings estimates for the current year have been revised 12% upward over the last 60 days. Also, its shares gained 16.2% in a year’s time. The stock currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Lazard’s current-year earnings estimates have been revised 3.1% upward over the last 60 days. Its shares increased 12.4% in the last year. It has a Zacks Rank #2 (Buy).
Virtus Investment Partners also carries a Zacks Rank of 2. Its current-year earnings estimates have been revised 4.1% upward over the last 60 days. Its share price has increased 17.1% in the last year.
Investor Alert: Breakthroughs Pending
A medical advance is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating substantial revenue, and even more wondrous products are in the pipeline.
Cures for a variety of deadly diseases are in sight, and so are big potential profits for early investors. Zacks names 5 stocks to buy now.
Click here to see them >>